Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: FRUTIGA was the first China combination trial initiated as part of HUTCHMED’s broad fruquintinib development programme in China and globally as monotherapy and in combinations. The strategy has since evolved to focus on immuno-oncology combinations (detailed in our September 2022 Pipeline Update), reflecting advances in the SoC in several indications and leveraging fruquintinib’s profile as a safe and highly selective potent VEGFR 1/2/3 inhibitor, with potentially synergistic mechanisms of action. Fruquintinib is a key contributor to HUTCHMED FY22 China revenue guidance of $160-$190m and, assuming a positive decision in 2024 from the FDA, EMA, and/or PMDA, could become its first approval ex-China.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.